Navigation Links
Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
Date:10/26/2009

LA JOLLA, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced that the presentation given by Dr. Juliet Singh, President and Chief Executive Officer of Transdel, at the 4th annual BIOCOM Investor Conference, will be webcast live.

Dr. Singh's presentation will take place today, Monday, October 26, 2009 at 4:00 p.m., PDT (7:00 p.m., EDT). Interested parties can access a live audio webcast via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel®, the Company's lead pain product, has successfully completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel(TM) platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. In June 2009, the Company announced that they entered into a license agreement with JH Direct, LLC for the exclusive worldwide rights to Transdel's anti-cellulite cosmeceutical product which utilizes the Company's Transdel(TM) technology. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel(®); the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the outcome of the final analyses of the data from the Phase 3 clinical trial may vary from the Company's initial conclusions; the FDA may not agree with the Company's interpretation of such results or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may continue to require the Company to complete additional clinical trials for Ketotransdel(®) before the Company can submit a 505(b)2 NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel(®); and the Company's current need to raise additional funding to complete its product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

SOURCE Transdel Pharmaceuticals, Inc.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
5. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
6. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
7. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
8. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
9. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... 2017 Pace Analytical, a company of over 2,000 employees and a ... acquired ESC Lab Sciences, further solidifying their position as the top American owned ... ... CEO of Pace Analytical ... of Mt Juliet, TN , enhances Pace Analytical,s capability as ...
(Date:6/30/2017)... (AVACEN) announced the publication of new research in the peer-reviewed Fibromyalgia ... AVACEN Treatment Method to significantly reduce the widespread pain symptom ... ... ... to 400 million people worldwide according to The National Fibromyalgia Association. ...
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
Breaking Medicine Technology:
(Date:7/20/2017)... Minneapolis, Minnesota (PRWEB) , ... July 19, 2017 ... ... in healthcare experience, recently hiring senior healthcare project manager, Josh Christensen. As a ... the nation and looks to further its healthcare resume in the Midwest with ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s ... Bieniek. Edward Steven Bieniek Jr. was born in Toledo, Ohio. He attended Woodward ... tech. He is married to a brilliant woman with a caring heart named Tiina, ...
(Date:7/18/2017)... ... ... an international clinical trial, led in part by a UC Davis School of Medicine expert, ... for a subgroup of patients. , In a paper just published online in the journal ... 18 countries describe the clinical benefit of using the drug ataluren for a certain group ...
(Date:7/18/2017)... ... , ... Heritage Woods of Benton, a Gardant affordable assisted living community is ... , The community, which is located at 1305 Bailey Lane in Benton, Illinois, serves ... maintain their independence. , The lunch menu will include Hawaiian chicken, meatballs and coleslaw. ...
(Date:7/17/2017)... ... July 18, 2017 , ... ... PICOPLUS 450 ps pulse width and a new published paper entitled ‘Pattern ... in tissue-mimicking phantom’ featured in Nature’s specialty journal Scientific Reports May 08, ...
Breaking Medicine News(10 mins):